Johnson & Johnson said it sold $ 502 million worth of Covid-19 vaccines in its third-quarter income statement, which beat Wall Street’s expectations.
Here are J&J’s results compared to Wall Street’s expectations, according to the average estimates compiled by Refinitiv:
- Adjusted earnings per share: $ 2.60 per share versus $ 2.35 expected.
- Revenue: $ 23.34 billion vs. $ 23.72 billion expected
J&J shares jumped more than 1% in the premarket.
J&J’s report has been criticized over how the company has handled the opioid crisis and the development of a relatively less effective Covid vaccine under the leadership of outgoing CEO Alex Gorski.
In a press release, Gorski said the financial results “show solid results from Johnson & Johnson, driven by robust out-of-market results in pharmaceuticals, continued recovery in the medical device industry and strong growth in consumer healthcare.”
This is an evolving story. Please stay tuned.
Bugfix: This story has been updated to reflect that J&J missed revenue estimates.